<?xml version="1.0" encoding="ASCII"?>
<biogps><data><item key="owner">ArrayExpress Uploader</item><item key="ownerprofile_id">arrayexpress_sid</item><item key="species">human</item><item key="factors"><item><item key="CIT-HS-NATL-PG-S01"><item key="SampleType">tissue</item><item key="Age">68</item><item key="DiseaseStage">4</item><item key="Age(years)">  </item><item key="DiseaseState">angioimmunoblastic T-cell lymphoma</item></item></item><item><item key="CIT-HS-NATL-PG-S02"><item key="SampleType">tissue</item><item key="Age">71</item><item key="DiseaseStage">3</item><item key="Age(years)">  </item><item key="DiseaseState">angioimmunoblastic T-cell lymphoma</item></item></item><item><item key="CIT-HS-NATL-PG-S03"><item key="SampleType">tissue</item><item key="Age">53</item><item key="DiseaseStage">n/a</item><item key="Age(years)">  </item><item key="DiseaseState">angioimmunoblastic T-cell lymphoma</item></item></item><item><item key="CIT-HS-NATL-PG-S04"><item key="SampleType">tissue</item><item key="Age">59</item><item key="DiseaseStage">n/a</item><item key="Age(years)">  </item><item key="DiseaseState">angioimmunoblastic T-cell lymphoma</item></item></item><item><item key="CIT-HS-NATL-PG-S05"><item key="SampleType">tissue</item><item key="Age">65</item><item key="DiseaseStage">4</item><item key="Age(years)">  </item><item key="DiseaseState">angioimmunoblastic T-cell lymphoma</item></item></item><item><item key="CIT-HS-NATL-PG-S06"><item key="SampleType">tissue</item><item key="Age">50</item><item key="DiseaseStage">4</item><item key="Age(years)">  </item><item key="DiseaseState">angioimmunoblastic T-cell lymphoma</item></item></item><item><item key="CIT-HS-NATL-PG-S07"><item key="SampleType">tissue</item><item key="Age">74</item><item key="DiseaseStage">4</item><item key="Age(years)">  </item><item key="DiseaseState">angioimmunoblastic T-cell lymphoma</item></item></item><item><item key="CIT-HS-NATL-PG-S08"><item key="SampleType">tissue</item><item key="Age">75</item><item key="DiseaseStage">4</item><item key="Age(years)">  </item><item key="DiseaseState">angioimmunoblastic T-cell lymphoma</item></item></item><item><item key="CIT-HS-NATL-PG-S09"><item key="SampleType">tissue</item><item key="Age">81</item><item key="DiseaseStage">4</item><item key="Age(years)">  </item><item key="DiseaseState">angioimmunoblastic T-cell lymphoma</item></item></item><item><item key="CIT-HS-NATL-PG-S10"><item key="SampleType">tissue</item><item key="Age">53</item><item key="DiseaseStage">4</item><item key="Age(years)">  </item><item key="DiseaseState">angioimmunoblastic T-cell lymphoma</item></item></item><item><item key="CIT-HS-NATL-PG-S11"><item key="SampleType">tissue</item><item key="Age">64</item><item key="DiseaseStage">4</item><item key="Age(years)">  </item><item key="DiseaseState">angioimmunoblastic T-cell lymphoma</item></item></item><item><item key="CIT-HS-NATL-PG-S12"><item key="SampleType">tissue</item><item key="Age">71</item><item key="DiseaseStage">4</item><item key="Age(years)">  </item><item key="DiseaseState">angioimmunoblastic T-cell lymphoma</item></item></item><item><item key="CIT-HS-NATL-PG-S13"><item key="SampleType">tissue</item><item key="Age">69</item><item key="DiseaseStage">3</item><item key="Age(years)">  </item><item key="DiseaseState">angioimmunoblastic T-cell lymphoma</item></item></item><item><item key="CIT-HS-NATL-PG-S14"><item key="SampleType">tissue</item><item key="Age">83</item><item key="DiseaseStage">n/a</item><item key="Age(years)">  </item><item key="DiseaseState">angioimmunoblastic T-cell lymphoma</item></item></item><item><item key="CIT-HS-NATL-PG-S02"><item key="SampleType">tissue</item><item key="Age">71</item><item key="DiseaseStage">3</item><item key="Age(years)">  </item><item key="DiseaseState">angioimmunoblastic T-cell lymphoma</item></item></item><item><item key="CIT-HS-NATL-PG-S16"><item key="SampleType">tissue</item><item key="Age">81</item><item key="DiseaseStage">n/a</item><item key="Age(years)">  </item><item key="DiseaseState">angioimmunoblastic T-cell lymphoma</item></item></item><item><item key="CIT-HS-NATL-PG-S17"><item key="SampleType">tissue</item><item key="Age">67</item><item key="DiseaseStage">4</item><item key="Age(years)">  </item><item key="DiseaseState">angioimmunoblastic T-cell lymphoma</item></item></item><item><item key="CIT-HS-NATL-PG-S17C"><item key="SampleType">sorted cells</item><item key="Age">  </item><item key="DiseaseStage">n/a</item><item key="Age(years)">n/a</item><item key="DiseaseState">angioimmunoblastic T-cell lymphoma</item></item></item><item><item key="CIT-HS-NATL-PG-S18C"><item key="SampleType">sorted cells</item><item key="Age">54</item><item key="DiseaseStage">4</item><item key="Age(years)">  </item><item key="DiseaseState">angioimmunoblastic T-cell lymphoma</item></item></item><item><item key="CIT-HS-NATL-PG-S19"><item key="SampleType">tissue</item><item key="Age">21</item><item key="DiseaseStage">4</item><item key="Age(years)">  </item><item key="DiseaseState">peripheral T-cell lymphoma, not otherwise specified</item></item></item><item><item key="CIT-HS-NATL-PG-S20"><item key="SampleType">tissue</item><item key="Age">69</item><item key="DiseaseStage">4</item><item key="Age(years)">  </item><item key="DiseaseState">peripheral T-cell lymphoma, not otherwise specified</item></item></item><item><item key="CIT-HS-NATL-PG-S21"><item key="SampleType">tissue</item><item key="Age">45</item><item key="DiseaseStage">4</item><item key="Age(years)">  </item><item key="DiseaseState">peripheral T-cell lymphoma, not otherwise specified</item></item></item><item><item key="CIT-HS-NATL-PG-S22"><item key="SampleType">tissue</item><item key="Age">77</item><item key="DiseaseStage">3</item><item key="Age(years)">  </item><item key="DiseaseState">peripheral T-cell lymphoma, not otherwise specified</item></item></item><item><item key="CIT-HS-NATL-PG-S23"><item key="SampleType">tissue</item><item key="Age">59</item><item key="DiseaseStage">4</item><item key="Age(years)">  </item><item key="DiseaseState">peripheral T-cell lymphoma, not otherwise specified</item></item></item><item><item key="CIT-HS-NATL-PG-S24"><item key="SampleType">tissue</item><item key="Age">69</item><item key="DiseaseStage">1</item><item key="Age(years)">  </item><item key="DiseaseState">peripheral T-cell lymphoma, not otherwise specified</item></item></item><item><item key="CIT-HS-NATL-PG-S25"><item key="SampleType">tissue</item><item key="Age">63</item><item key="DiseaseStage">3</item><item key="Age(years)">  </item><item key="DiseaseState">peripheral T-cell lymphoma, not otherwise specified</item></item></item><item><item key="CIT-HS-NATL-PG-S26"><item key="SampleType">tissue</item><item key="Age">32</item><item key="DiseaseStage">3</item><item key="Age(years)">  </item><item key="DiseaseState">peripheral T-cell lymphoma, not otherwise specified</item></item></item><item><item key="CIT-HS-NATL-PG-S27"><item key="SampleType">tissue</item><item key="Age">56</item><item key="DiseaseStage">4</item><item key="Age(years)">  </item><item key="DiseaseState">peripheral T-cell lymphoma, not otherwise specified</item></item></item><item><item key="CIT-HS-NATL-PG-S28"><item key="SampleType">tissue</item><item key="Age">62</item><item key="DiseaseStage">4</item><item key="Age(years)">  </item><item key="DiseaseState">peripheral T-cell lymphoma, not otherwise specified</item></item></item><item><item key="CIT-HS-NATL-PG-S29"><item key="SampleType">tissue</item><item key="Age">57</item><item key="DiseaseStage">4</item><item key="Age(years)">  </item><item key="DiseaseState">peripheral T-cell lymphoma, not otherwise specified</item></item></item><item><item key="CIT-HS-NATL-PG-S30"><item key="SampleType">tissue</item><item key="Age">66</item><item key="DiseaseStage">4</item><item key="Age(years)">  </item><item key="DiseaseState">peripheral T-cell lymphoma, not otherwise specified</item></item></item><item><item key="CIT-HS-NATL-PG-S31"><item key="SampleType">tissue</item><item key="Age">35</item><item key="DiseaseStage">1</item><item key="Age(years)">  </item><item key="DiseaseState">peripheral T-cell lymphoma, not otherwise specified</item></item></item><item><item key="CIT-HS-NATL-PG-S32"><item key="SampleType">tissue</item><item key="Age">67</item><item key="DiseaseStage">3</item><item key="Age(years)">  </item><item key="DiseaseState">peripheral T-cell lymphoma, not otherwise specified</item></item></item><item><item key="CIT-HS-NATL-PG-S33"><item key="SampleType">tissue</item><item key="Age">42</item><item key="DiseaseStage">4</item><item key="Age(years)">  </item><item key="DiseaseState">peripheral T-cell lymphoma, not otherwise specified</item></item></item><item><item key="CIT-HS-NATL-PG-S34"><item key="SampleType">tissue</item><item key="Age">54</item><item key="DiseaseStage">4</item><item key="Age(years)">  </item><item key="DiseaseState">peripheral T-cell lymphoma, not otherwise specified</item></item></item></item><item key="id">5247</item><item key="pop_total">0</item><item key="platform">4</item><item key="summary_wrapped">[u'A \uff91Cartes d\uff92Identite des Tumeurs\uff92 (CIT) project from the french Ligue Nationale Contre le Cancer (', {u'a': {u'href':...</item><item key="pubmed_id">17284527</item><item key="geo_gse_id">E-TABM-783</item><item key="owner_profile">/profile/8773/arrayexpressuploader</item><item key="factor_count">5</item><item key="sample_count">35</item><item key="tags"><item>cancer</item><item>cell</item><item>dendritic</item><item>follicular dendritic cell</item><item>lymphoma</item><item>peripheral</item><item>peripheral t-cell lymphoma</item></item><item key="lastmodified">Dec.12, 2014</item><item key="is_default">False</item><item key="geo_gds_id"/><item key="slug">transcription-profiling-of-human-non-anaplastic-t</item><item key="geo_id_plat">E-TABM-783_A-AFFY-44</item><item key="name">Transcription profiling of human non anaplastic T-cell lymphoma</item><item key="created">Sep.22, 2014</item><item key="summary">[u'A \uff91Cartes d\uff92Identite des Tumeurs\uff92 (CIT) project from the french Ligue Nationale Contre le Cancer (', {u'a': {u'href': u'http://cit.ligue-cancer.net', u'target': u'_blank', u'$': u'http://cit.ligue-cancer.net'}}, u') | Affymetrix HG-U133 Plus 2.0 : 17 AITL biopsies, 2 AITL sorted cells, 16 PTCL NOS biopsies | The molecular alterations underlying the pathogenesis of angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma, unspecified (PTCL-u) are largely unknown. In order to characterize the ontogeny and molecular differences between both entities, a series of AITLs (n = 18) and PTCLs-u (n = 16) was analyzed using gene expression profiling. Unsupervised clustering correlated with the pathological classification and with CD30 expression in PTCL-u. The molecular profile of AITLs was characterized by a strong microenvironment imprint (overexpression of B-cell- and follicular dendritic cell-related genes, chemokines, and genes related to extracellular matrix and vascular biology), and overexpression of several genes characteristic of normal follicular helper T (T(FH)) cells (CXCL13, BCL6, PDCD1, CD40L, NFATC1). By gene set enrichment analysis, the AITL molecular signature was significantly enriched in published T(FH)-specific genes. The enrichment was higher for sorted AITL cells than for tissue samples. Overexpression of several T(FH) genes was validated by immunohistochemistry in AITLs. A few cases with molecular T(FH)-like features were identified among CD30(-) PTCLs-u. Our findings strongly support that T(FH) cells represent the normal counterpart of AITL, and suggest that the AITL spectrum may be wider than suspected, as a subset of CD30(-) PTCLs-u may derive from or be related to AITL.| Submitter : Aurelien de Reynies &lt;reyniesa@ligue-cancer.fr&gt; | Project leader : Philippe Gaulard &lt;philippe.gaulard@hmn.aphp.fr&gt;']</item><item key="source">http://www.ebi.ac.uk/arrayexpress/experiments/E-TABM-783</item><item key="sample_source">http://www.ebi.ac.uk/arrayexpress/experiments/E-TABM-783/samples/</item></data></biogps>
